Clinical trials: Non-Small-Cell Lung
Non-Small Cell Lung Cancer
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
This is a randomized, open-label, multi-center, Phase II study of treatment of patients with advanced NSCLC who have progressed on erlotinib with the combination of sorafenib and erlotinib or sorafenib alone.
- Trial name
- NCT00609804
- Testing
- Sorafenib, Erlotinib
- Where
- 16 sites in United States
- Volunteers
- 53 people
- Sponsor
- SCRI Development Innovations, LLC
Sarcopenia, Non Small Cell Lung Cancer
Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer
Growing evidence has confirmed that the prognosis of lung cancer is not only related to the stage of disease, but also to the physiological and psychological situation of the patients.
- Conditions
- Sarcopenia, Non Small Cell Lung Cancer, Malnutrition
- Trial name
- NCT05212285
- Testing
- Inbody 570, JAMAR Dynamometer, CT scan
- Where
- China
- Volunteers
- 469 people
- Sponsor
- Fudan University
Malignant Pericardial Effusion, Malignant Pleural Effusion
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
This randomized clinical trial studies how well genetic sequencing-informed targeted therapy works in treating patients with stage IIIB-IV non-small cell lung cancer.
- Conditions
- Malignant Pericardial Effusion, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT02132884
- Testing
- cytology specimen collection procedure, therapeutic procedure, targeted therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Fox Chase Cancer Center
Non-Small-Cell Lung Cancer
Phase II Trial of Continuation Therapy in Advanced NSCLC
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit (CR, PR, or SD ≥ 3 months) with a PD-1 or PD-L1 inhibitor.
- Trial name
- NCT03083808
- Testing
- Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Greg Durm, MD
Carcinoma, Non-Small-Cell Lung
Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer
Investigate the effect of multiple oral doses of nintedanib on the single dose kinetics of a combination of ethinylestradiol and levonorgestrel (Microgynon®)
- Trial name
- NCT02751385
- Testing
- Microgynon, Nintedanib
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02552121
- Testing
- Tisotumab vedotin (HuMax-TF-ADC)
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Mesothelioma, Mesotheliomas Pleural
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum
- Trial name
- NCT05451849
- Testing
- TC-510, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- TCR2 Therapeutics
Non-Small Cell Lung Carcinoma
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
This is a study to assess the efficacy and safety of pembrolizumab (MK-3475/SCH 900475) compared to standard of care (SOC) platinum-based chemotherapies in the treatment of participants with previously untreated stage IV…
- Trial name
- NCT02142738
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Volunteers
- 305 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced Non-Small Cell Lung Cancer
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
This is a phase I, open-label trial that will utilise a Time To Event Continual Reassessment Method (TiTE-CRM) to determine the maximum tolerated dose (MTD) of atovaquone in combination with concurrent CRT in NSCLC.
- Trial name
- ARCADIAN (NCT04648033)
- Testing
- Atovaquone Oral Suspension, Standard of care chemotherapy, Standard of care radiotherapy
- Where
- 3 sites in United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Oxford
Advanced Solid Tumors
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.
- Trial name
- NCT06039384
- Testing
- INCB099280, adagrasib
- Where
- 14 sites in United States, Italy and 2 more
- Volunteers
- 6 people
- Sponsor
- Incyte Corporation
Lung Cancer
Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with…
- Trial name
- NCT00008385
- Testing
- selenium
- Where
- 532 sites in United States, Canada
- Volunteers
- 1,772 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non-Small Cell Lung Cancer
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung…
- Trial name
- NCT02544633
- Testing
- MGCD265
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 68 people
- Sponsor
- Mirati Therapeutics Inc.
Non-small Cell Lung Cancer, Mesothelioma
Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
This study will test the effects of pemetrexed on mesothelioma and non-small cell lung cancer patients with fluid around their lungs or abdomen.
- Conditions
- Non-small Cell Lung Cancer, Mesothelioma, Lung Neoplasms
- Trial name
- NCT00316225
- Testing
- pemetrexed
- Where
- 3 sites in Denmark, Germany and 1 more
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)
To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT00191191
- Testing
- Pemetrexed 500 mg/m2, Pemetrexed 1000 mg/m2
- Where
- 16 sites in Japan
- Volunteers
- 226 people
- Sponsor
- Eli Lilly and Company
Stage III Non-small-cell Lung Cancer
Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
Elderly (age 70 years or older) or >18 years old AND poor risk (ECOG 2) newly diagnosed stage IIIA-C (AJCC 8th edition) inoperable non-small cell lung cancer (NSCLC) patients are eligible to participate in this phase II open…
- Trial name
- ESR1814205 (NCT04441138)
- Testing
- Durvalumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rush University Medical Center
Advanced Non-small Cell Lung Cancer
AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer
This clinical study is looking at a vaccine called AST-VAC2 in adult patients with advanced non-small cell lung cancer (NSCLC). The main aim of the study: If the dose can be given safely to patients, learn more about the…
- Trial name
- NCT03371485
- Testing
- AST-VAC2
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Cancer Research UK
Non-small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], followed by pembrolizumab alone after surgery…
- Trial name
- NCT03425643
- Testing
- Pembrolizumab, Cisplatin, Gemcitabine
- Where
- 227 sites in United States, Argentina and 23 more
- Volunteers
- 797 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare…
- Trial name
- NCT03052608
- Testing
- Lorlatinib, Crizotinib
- Where
- 166 sites in United States, Argentina and 21 more
- Volunteers
- 296 people
- Sponsor
- Pfizer
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Non-Small Cell Lung Cancer
A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone
The purpose of this study is to assess the efficacy and safety of gefitinib in patients who have progressed on first line gefitinib, comparing continuing gefitinib in addition to cisplatin plus pemetrexed combination chemotherapy…
- Trial name
- IMPRESS (NCT01544179)
- Testing
- Gefitinib, Pemetrexed, Cisplatin
- Where
- 61 sites in China, France and 9 more
- Volunteers
- 265 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.